Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort

Title: Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort
Authors: Quaranta, Maria Giovanna; Ferrigno, Luigina; Monti, Monica; Filomia, Roberto; Biliotti, Elisa; Iannone, Andrea; Migliorino, Guglielmo; Coco, Barbara; Morisco, Filomena; Vinci, Maria; D'Ambrosio, Roberta; Chemello, Liliana; Massari, Marco; Ieluzzi, Donatella; Russo, Francesco Paolo; Blanc, Pierluigi; Verucchi, Gabriella; Puoti, Massimo; Rumi, Maria Grazia; Barbaro, Francesco; Santantonio, Teresa Antonia; Federico, Alessandro; Chessa, Luchino; Gentile, Ivan; Zuin, Massimo; Parruti, Giustino; Morsica, Giulia; Kondili, Loreta A; Segala D.
Contributors: Quaranta, Maria Giovanna; Ferrigno, Luigina; Monti, Monica; Filomia, Roberto; Biliotti, Elisa; Iannone, Andrea; Migliorino, Guglielmo; Coco, Barbara; Morisco, Filomena; Vinci, Maria; D'Ambrosio, Roberta; Chemello, Liliana; Massari, Marco; Ieluzzi, Donatella; Russo, Francesco Paolo; Blanc, Pierluigi; Verucchi, Gabriella; Puoti, Massimo; Rumi, Maria Grazia; Barbaro, Francesco; Santantonio, Teresa Antonia; Federico, Alessandro; Chessa, Luchino; Gentile, Ivan; Zuin, Massimo; Parruti, Giustino; Morsica, Giulia; Kondili, Loreta A; Segala, D.
Publication Year: 2020
Collection: Università degli Studi di Ferrara: CINECA IRIS
Subject Terms: Advanced liver disease; Cirrhosi; Clinical outcome; Coinfection; Direct-acting antiviral; Hepatitis C viru; Hepatocellular carcinoma; Human immunodeficiency viru; Real-life cohort; Sustained virological response; Viral eradication
Description: Background: Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-acting antiviral (DAA) treatment in the real-life setting according to Human Immunodeficiency Virus (HIV) coinfection was evaluated. Methods: Patients consecutively enrolled in PITER between April 2014 and June 2019 and with at least 12-weeks follow-up following treatment were analysed. Cox regression analysis were used to evaluate HIV coinfection and factors independently associated with liver disease outcomes following viral eradication in DAA treated patients with pre-treatment liver cirrhosis. Results: 93 HIV/HCV coinfected and 1109 HCV monoinfected patients were evaluated during a median follow-up of 26.7 (range 6–44.6) and 24.6 (range 6.8–47.3) months, respectively. No difference in the cumulative HCC incidence and hepatic decompensation was observed between coinfected and monoinfected patients. Age (Hazard Ratio [HR] = 1.08; 95% CI 1.04–1.13), male sex (HR = 2.76; 95% CI 1.28–5.96), lower albumin levels (HR = 3.94; 95% CI 1.81–8.58), genotype 3 (HR = 5.05; 95% CI 1.75–14.57) and serum anti-HBc positivity (HR = 1.99, 95% CI 1.01–3.95) were independently associated with HCC incidence. Older age (HR = 1.03; 95% CI 1.00–1.07), male sex (HR = 2.13; 95% CI 1.06–4.26) and lower albumin levels (HR = 3.75; 95% CI 1.89–7.46) were independently associated with the appearance of a decompensating event after viral eradication. Conclusion: Different demographic, clinical and genotype distribution between HIV coinfected vs those monoinfected, was observed in a representative cohort of HCV infected patients in Italy. Once liver cirrhosis is established the disease progression is decreased, but still persists regardless of viral eradication in both coinfected and monoinfected patients. In patients with cirrhosis, HIV coinfection was not associated with a higher probability of liver complications, after viral eradication.
Document Type: article in journal/newspaper
File Description: STAMPA
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/32279177; info:eu-repo/semantics/altIdentifier/wos/WOS:000525152000001; volume:14; issue:3; firstpage:362; lastpage:372; numberofpages:11; journal:HEPATOLOGY INTERNATIONAL; https://hdl.handle.net/11392/2418647
DOI: 10.1007/s12072-020-10034-0
DOI: 10.1007/s12072-020-10034-0.pdf
Availability: https://hdl.handle.net/11392/2418647; https://doi.org/10.1007/s12072-020-10034-0; https://link.springer.com/content/pdf/10.1007/s12072-020-10034-0.pdf; https://link.springer.com/article/10.1007/s12072-020-10034-0
Rights: info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.20CD7A73
Database: BASE